Valuation: Eagle Pharmaceuticals, Inc.

Market Cap 67.92M 59.04M 54.96M 50.46M 95.29M 6.48B 96.76M 648M 254M 3.23B 255M 249M 10.82B P/E 2021
-77x
P/E 2022 10.7x
Enterprise Value 78.11M 67.9M 63.2M 58.03M 110M 7.46B 111M 745M 292M 3.71B 293M 287M 12.45B EV / Sales 2021
3.44x
EV / Sales 2022 1.23x
Free-Float
74.04%
Yield 2021 *
-
Yield 2022 -
1 day+94.27%
1 week-47.27%
Current month-47.27%
1 month-70.88%
3 months-58.93%
6 months-21.96%
Current year-72.13%
1 month 0.06
Extreme 0.0566
0.64
Current year 0
Extreme 0.0011
0.85
1 year 0
Extreme 0.0011
3.72
3 years 0
Extreme 0.0011
23.52
5 years 0
Extreme 0.0011
58.25
10 years 0
Extreme 0.0011
97.15
Manager TitleAgeSince
Chief Executive Officer 63 2023-11-26
Director of Finance/CFO 52 2024-11-10
Corporate Officer/Principal - 2022-07-17
Director TitleAgeSince
Director/Board Member 83 2007-02-28
Chairman 63 2016-06-28
Director/Board Member 65 2016-06-30
Date Insider Type Main position Quantity % Market Cap.
2/28/24 Tax 2,119 0.0163%
2/27/24 Free 16,104 0.1240%
2/27/24 Free

Chief Financial Officer

5,389 0.0415%
Change 5-day change 1-year change 3-year change Capi.($)
+94.27%-47.27%-93.88%-99.07% 4.82M
+0.32%-0.66%+64.21%+23.67% 322B
+0.21%+2.87%+33.60%-10.34% 71.6B
-0.91%+0.74%+39.85%+95.22% 9.79B
-3.60%-2.43%-1.16%-6.92% 8.39B
+1.80%-1.99%-15.78%-12.22% 4.3B
-0.68%-1.87%-34.78%+3.04% 3.81B
+3.08%-1.41%-12.94%+9.52% 3.58B
-2.15%-3.40%+25.70%+40.83% 2.59B
+0.85%+9.88%-0.25%-7.32% 2.25B
Average +9.32%-0.30%+0.46%+3.64% 42.79B
Weighted average by Cap. +0.21%-0.09%+54.34%+18.29%

Financials

2021 2022
Net sales 172M 149M 139M 127M 241M 16.38B 244M 1.64B 642M 8.15B 644M 630M 27.34B 317M 275M 256M 235M 444M 30.22B 451M 3.02B 1.19B 15.05B 1.19B 1.16B 50.45B
Net income -8.63M -7.5M -6.98M -6.41M -12.1M -824M -12.29M -82.28M -32.29M -410M -32.4M -31.69M -1.37B 35.64M 30.98M 28.84M 26.48M 50M 3.4B 50.78M 340M 133M 1.69B 134M 131M 5.68B
Net Debt -67.84M -58.97M -54.89M -50.4M -95.17M -6.48B -96.64M -647M -254M -3.22B -255M -249M -10.81B 10.19M 8.86M 8.24M 7.57M 14.29M 972M 14.51M 97.16M 38.13M 484M 38.26M 37.42M 1.62B
Logo Eagle Pharmaceuticals, Inc.
Eagle Pharmaceuticals, Inc. is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial specializations. The Company is focused on developing medicines that result in improvements in patients' lives. The Company's commercialized products include PEMFEXY, RYANODEX, BENDEKA, BELRAPZO, TREAKISYM (Japan), and BYFAVO through its wholly owned subsidiary Acacia Pharma Inc. The Company’s oncology and CNS/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. Its pipeline includes ENA-001 and EA-114. EA-114 is a novel and proprietary formulation of fulvestrant being developed for hormone-receptor-positive (HR+) metastatic breast cancer. ENA-001 is an investigational new chemical entity being developed by the Company’s partner, Enalare, as an agnostic respiratory stimulant for multiple patient populations experiencing respiratory depression.
Employees
134
Date Price Change Volume
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. EGRX Stock